AGW-11

AGW-11 is a potent dual inhibitor of EGFR (IC50 = 556 nM) and VEGFR2 (IC50 = 289.7 nM) . AGW-11 induces apoptosis and suppresses phosphorylation of EGFR, VEGFR2, and ERK1/2 in HUVECs. AGW-11 effectively inhibits cancer cell growth, reduces HUVEC proliferation, tube formation, and invasion, thereby blocking angiogenesis. AGW-11 significantly suppresses tumor growth and decreases lung metastasis in a 4T1 xenograft mouse model. AGW-11 can be used for the study of breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR; ERK; VEGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Smiles

CC(OC[C@]([C@]1([H])[C@@]([C@H](C/C=C2C(OC[C@@H]/2OC3=C4N=CC=CC4=CC=C3)=O)C(CC1)=C)(C)CC5)(C)NC5=O)=O

Molecular Formula

C31H36N2O6

Molecular Weight

532.63

References & Citations

[1]Chen R, et al. Design and synthesis of lactam analogs of andrographolide and discovery of their anticancer activity as dual EGFR and VEGFR2 inhibitors. Eur J Med Chem. 2025 Dec 5;299:118042.